ALNYLAM PHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense in USD from 2010 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Alnylam Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2010 to 2023.
  • Alnylam Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $45.8M, a 28.4% decline year-over-year.
  • Alnylam Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $222M, a 0.01% decline year-over-year.
  • Alnylam Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $222M, a 3.89% decline from 2022.
  • Alnylam Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $231M, a 39.2% increase from 2021.
  • Alnylam Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $166M, a 18.5% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $222M -$8.97M -3.89% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-15
2022 $231M +$64.9M +39.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-15
2021 $166M +$25.8M +18.5% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-15
2020 $140M -$35M -20% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 $175M +$17.1M +10.8% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-10
2018 $158M +$64.9M +70% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-11
2017 $92.8M Jan 1, 2017 Dec 31, 2017 10-K 2020-02-13
2012 $12.7M -$4.4M -25.7% Jan 1, 2012 Dec 31, 2012 10-K 2013-02-19
2011 $17.1M -$2.3M -11.9% Jan 1, 2011 Dec 31, 2011 10-K 2013-02-19
2010 $19.4M Jan 1, 2010 Dec 31, 2010 10-K 2013-02-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.